Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18369540 | 0.89 | MAPT (0.39) | NPC1MAPTF11DGAT1KLKB1 | |
| SCHEMBL30690630 | 0.86 | NPC1 (0.39) | NPC1MAPTF11DGAT1MGAM | |
| SCHEMBL18369539 | 0.82 | MAPT (0.36) | NPC1MAPTF11DGAT1 | |
| SCHEMBL18422264 | 0.80 | NPC1 (0.42) | NPC1MAPTF11DGAT1KLKB1 | |
| SCHEMBL30690764 | 0.79 | CHEK1 (0.39) | NPC1MAPTDGAT1 | |
| SCHEMBL18369614 | 0.79 | MAPT (0.33) | NPC1MAPTDGAT1 | |
| SCHEMBL21818822 | 0.79 | ADORA3 (0.38) | NPC1MAPTDGAT1MGAMKLKB1 | |
| SCHEMBL12670986 | 0.78 | DGAT1 (0.39) | NPC1MAPTDGAT1MGAMKLKB1 | |
| SCHEMBL30285039 | 0.78 | DGAT1 (0.39) | NPC1MAPTDGAT1MGAMKLKB1 | |
| SCHEMBL30690792 | 0.77 | PIK3CD (0.34) | NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190002437-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002437-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | NPC1 959/4885MAPT 2802/4885F11 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.